Fady Ibraham Malik Cytokinetics Inc (CYTK) insider trading activity

Fady Ibraham Malik is EVP Research & Development of CYTOKINETICS INC. Currently has a direct ownership of 116,071 shares of CYTK, which is worth approximately $5.67 Million. The most recent transaction as insider was on May 11, 2023, when has been sold 1,787 shares (Common Stock) at a price of $39.5 per share, resulting in proceeds of $70,586. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 116K

4.01% 3M change

22.96% 12M change

Total Value Held $5.67 Million

Fady Ibraham Malik Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 11 2023	SELL Open market or private sale	$70,586 $39.5 p/Share	1,787 Reduced 1.07%	165,396 Common Stock
May 03 2023	SELL Open market or private sale	$280,000 $40.0 p/Share	7,000 Reduced 4.02%	167,183 Common Stock
May 03 2023	BUY Exercise of conversion of derivative security	$55,720 $7.96 p/Share	7,000 Added 3.86%	174,183 Common Stock
Apr 13 2023	SELL Open market or private sale	$136,840 $34.21 p/Share	4,000 Reduced 2.34%	167,183 Common Stock
Mar 09 2023	SELL Open market or private sale	$156,400 $39.1 p/Share	4,000 Reduced 2.28%	171,183 Common Stock
Mar 06 2023	SELL Payment of exercise price or tax liability	$194,006 $39.13 p/Share	4,958 Reduced 3.54%	135,183 Common Stock
Mar 06 2023	BUY Grant, award, or other acquisition	-	40,000 Added 18.59%	175,183 Common Stock
Mar 02 2023	SELL Payment of exercise price or tax liability	$427,086 $39.6 p/Share	10,785 Reduced 7.15%	140,141 Common Stock
Feb 16 2023	SELL Payment of exercise price or tax liability	$66,768 $44.13 p/Share	1,513 Reduced 0.99%	150,926 Common Stock
Feb 10 2023	SELL Bona fide gift	-	150 Reduced 0.1%	152,439 Common Stock
Feb 09 2023	SELL Open market or private sale	$174,920 $43.73 p/Share	4,000 Reduced 2.55%	152,589 Common Stock
Feb 09 2023	SELL Open market or private sale	$306,180 $43.74 p/Share	7,000 Reduced 4.28%	156,589 Common Stock
Feb 09 2023	BUY Exercise of conversion of derivative security	$55,720 $7.96 p/Share	7,000 Added 4.1%	163,589 Common Stock
Jan 12 2023	SELL Open market or private sale	$161,880 $40.47 p/Share	4,000 Reduced 2.49%	156,589 Common Stock
Dec 08 2022	SELL Open market or private sale	$145,120 $36.28 p/Share	4,000 Reduced 2.43%	160,589 Common Stock
Nov 10 2022	SELL Open market or private sale	$152,160 $38.04 p/Share	4,000 Reduced 2.38%	164,346 Common Stock
Oct 13 2022	SELL Open market or private sale	$1,017,135 $47.28 p/Share	21,513 Reduced 11.33%	168,346 Common Stock
Oct 13 2022	BUY Exercise of conversion of derivative security	$207,600 $9.65 p/Share	21,513 Added 10.18%	189,859 Common Stock
Sep 08 2022	SELL Open market or private sale	$1,115,420 $51.88 p/Share	21,500 Reduced 11.32%	168,346 Common Stock
Sep 08 2022	BUY Exercise of conversion of derivative security	$207,475 $9.65 p/Share	21,500 Added 10.17%	189,846 Common Stock
Jul 14 2022	SELL Open market or private sale	$933,745 $43.43 p/Share	21,500 Reduced 11.32%	168,346 Common Stock
Jul 14 2022	BUY Exercise of conversion of derivative security	$207,475 $9.65 p/Share	21,500 Added 10.17%	189,846 Common Stock
Jun 09 2022	SELL Open market or private sale	$873,330 $40.62 p/Share	21,500 Reduced 11.32%	168,346 Common Stock
Jun 09 2022	BUY Exercise of conversion of derivative security	$207,475 $9.65 p/Share	21,500 Added 10.17%	189,846 Common Stock
May 12 2022	SELL Open market or private sale	$525,072 $37.54 p/Share	13,987 Reduced 7.68%	168,084 Common Stock

Also insider at

RCKT

ROCKET PHARMACEUTICALS, INC. Healthcare

FIM